The Trump administration’s recent rule requiring pharmaceutical companies to include a drug’s list price in direct-to-consumer ads is a step in the right direction, albeit a “very tiny baby step,” American Council on Science and Health Senior Fellow Charles Dinerstein writes in a recent article.
While the prices displayed in the ads will be before including discounts and rebates, the rule, he writes, falls short of establishing a consistent way to glean accurate pricing information.
” … These newly announced measures, requiring an MSRP for pharmaceuticals, gives us regulation without any benefit, other than whatever political advantage accrues to those policymakers who are ‘trying,'” Dinerstein writes.
To read his full article on ACSH’s website, click here.
